Alcon has bolstered its glaucoma surgical device portfolio with the acquisition of Ivantis and its Hydrus Microstent. Alcon, a Switzerland-registered company with US headquarters in Texas, announced Nov. 8 that it would pay $475 million up front, plus potential milestone payments, for Ivantis, of Irvine, California. The transaction is expected to close in Q1-2022.
Glaukos Submits Supplemental Pre-Market Approval Application for iStent Infinite
Glaukos announced that it has submitted a supplemental pre-market approval (PMA) application to the FDA for the iStent infinite Trabecular Micro-Bypass System. The iStent infinite is an investigational device designed for use in a standalone procedure to reduce elevated IOP in patients with open-angle glaucoma uncontrolled by prior surgical or medical therapy. It includes three heparin-coated titanium stents preloaded into an auto-injection system that allows the …
Glaucoma Devices’ Expanding Role to Drive Double-Digit Market Growth
Glaucoma surgical devices will see increased use in all stages of disease and in stand-alone glaucoma procedures over the next 5 years, as companies commercialize more devices designed to meet these needs, according to a Market Scope report. Market Scope expects the glaucoma surgical device market to grow from nearly $800 million in 2021 to $1.7 billion in 2026, at …
Omni surgical system reduces IOP, medication use
The Omni surgical system reduced IOP through 3 months in patients with open-angle glaucoma, according to research presented at the American Society of Cataract and Refractive Surgery meeting. Brian Flowers, MD, presented 3-month interim data from the ORION study exploring the efficacy and safety of the Omni surgical system (Sight Sciences) in pseudophakic eyes with mild to moderate open-angle glaucoma. Patients …
